Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 18 studies | 26% ± 10% | |
classical monocyte | 15 studies | 25% ± 9% | |
oligodendrocyte | 15 studies | 50% ± 14% | |
macrophage | 12 studies | 25% ± 7% | |
monocyte | 9 studies | 35% ± 12% | |
type I pneumocyte | 9 studies | 34% ± 16% | |
non-classical monocyte | 9 studies | 26% ± 10% | |
GABAergic neuron | 9 studies | 42% ± 22% | |
glutamatergic neuron | 9 studies | 43% ± 25% | |
oligodendrocyte precursor cell | 9 studies | 30% ± 13% | |
microglial cell | 7 studies | 25% ± 6% | |
epithelial cell | 7 studies | 35% ± 16% | |
astrocyte | 7 studies | 31% ± 11% | |
natural killer cell | 6 studies | 22% ± 7% | |
interneuron | 6 studies | 43% ± 23% | |
dendritic cell | 6 studies | 25% ± 4% | |
neuron | 5 studies | 39% ± 15% | |
myeloid cell | 5 studies | 30% ± 11% | |
club cell | 5 studies | 25% ± 10% | |
ciliated cell | 5 studies | 23% ± 5% | |
T cell | 5 studies | 23% ± 5% | |
type II pneumocyte | 5 studies | 20% ± 5% | |
lymphocyte | 4 studies | 30% ± 10% | |
retina horizontal cell | 4 studies | 23% ± 5% | |
endothelial cell of lymphatic vessel | 4 studies | 24% ± 5% | |
conventional dendritic cell | 3 studies | 20% ± 1% | |
GABAergic interneuron | 3 studies | 30% ± 6% | |
granule cell | 3 studies | 25% ± 7% | |
CD16-negative, CD56-bright natural killer cell, human | 3 studies | 23% ± 1% | |
B cell | 3 studies | 23% ± 4% | |
alveolar macrophage | 3 studies | 51% ± 6% | |
CD16-positive, CD56-dim natural killer cell, human | 3 studies | 19% ± 3% | |
basal cell | 3 studies | 30% ± 19% | |
transit amplifying cell | 3 studies | 38% ± 26% | |
mast cell | 3 studies | 20% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 3259.67 | 1445 / 1445 | 100% | 90.32 | 183 / 183 |
lung | 100% | 3593.67 | 577 / 578 | 100% | 59.36 | 1155 / 1155 |
bladder | 100% | 3481.48 | 21 / 21 | 100% | 82.62 | 503 / 504 |
stomach | 100% | 2962.95 | 359 / 359 | 100% | 87.14 | 285 / 286 |
intestine | 100% | 2744.23 | 966 / 966 | 100% | 86.35 | 525 / 527 |
prostate | 100% | 2490.30 | 245 / 245 | 99% | 53.08 | 499 / 502 |
breast | 100% | 2367.68 | 459 / 459 | 99% | 55.50 | 1108 / 1118 |
uterus | 100% | 2736.39 | 170 / 170 | 99% | 57.82 | 453 / 459 |
thymus | 100% | 2622.72 | 653 / 653 | 99% | 53.82 | 597 / 605 |
ovary | 100% | 1944.35 | 180 / 180 | 99% | 43.22 | 424 / 430 |
brain | 99% | 3144.64 | 2623 / 2642 | 98% | 32.42 | 693 / 705 |
pancreas | 95% | 1110.14 | 313 / 328 | 98% | 61.55 | 175 / 178 |
adrenal gland | 100% | 1995.52 | 257 / 258 | 90% | 28.33 | 206 / 230 |
skin | 100% | 4164.82 | 1807 / 1809 | 89% | 45.12 | 419 / 472 |
kidney | 97% | 1147.88 | 86 / 89 | 82% | 24.31 | 737 / 901 |
liver | 99% | 1256.91 | 223 / 226 | 57% | 11.75 | 232 / 406 |
adipose | 100% | 2530.58 | 1204 / 1204 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 34.26 | 29 / 29 |
spleen | 100% | 3091.13 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 58.94 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 60.71 | 1 / 1 |
blood vessel | 100% | 2654.60 | 1334 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 5572.84 | 903 / 929 | 0% | 0 | 0 / 0 |
heart | 90% | 1012.55 | 777 / 861 | 0% | 0 | 0 / 0 |
muscle | 79% | 705.92 | 633 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 31% | 4.93 | 25 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016188 | Biological process | synaptic vesicle maturation |
GO_0018230 | Biological process | peptidyl-L-cysteine S-palmitoylation |
GO_0006612 | Biological process | protein targeting to membrane |
GO_0044794 | Biological process | positive regulation by host of viral process |
GO_0018345 | Biological process | protein palmitoylation |
GO_0005886 | Cellular component | plasma membrane |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0033116 | Cellular component | endoplasmic reticulum-Golgi intermediate compartment membrane |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0019705 | Molecular function | protein-cysteine S-myristoyltransferase activity |
GO_0016409 | Molecular function | palmitoyltransferase activity |
GO_0019706 | Molecular function | protein-cysteine S-palmitoyltransferase activity |
GO_0140439 | Molecular function | protein-cysteine S-stearoyltransferase activity |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | ZDHHC20 |
Protein name | Zinc finger DHHC-type palmitoyltransferase 20 Alternative protein ZDHHC20 Palmitoyltransferase (EC 2.3.1.225) Palmitoyltransferase ZDHHC20 (EC 2.3.1.225) (Acyltransferase ZDHHC20) (EC 2.3.1.-) (DHHC domain-containing cysteine-rich protein 20) (DHHC20) (Zinc finger DHHC domain-containing protein 20) |
Synonyms | |
Description | FUNCTION: Palmitoyltransferase that could catalyze the addition of palmitate onto various protein substrates . Catalyzes palmitoylation of Cys residues in the cytoplasmic C-terminus of EGFR, and modulates the duration of EGFR signaling by modulating palmitoylation-dependent EGFR internalization and degradation . Has a preference for acyl-CoA with C16 fatty acid chains . Can also utilize acyl-CoA with C14 and C18 fatty acid chains . .; FUNCTION: (Microbial infection) Dominant palmitoyltransferase responsible for lipidation of SARS coronavirus-2/SARS-CoV-2 spike protein. Through a sequential action with ZDHHC9, rapidly and efficiently palmitoylates spike protein following its synthesis in the endoplasmic reticulum (ER). In the infected cell, promotes spike biogenesis by protecting it from premature ER degradation, increases half-life and controls the lipid organization of its immediate membrane environment. Once the virus has formed, spike palmitoylation controls fusion with the target cell. . |
Accessions | ENST00000400590.8 [Q5W0Z9-1] A0A8V8TR49 ENST00000626464.2 ENST00000415724.2 [Q5W0Z9-1] B4DRN8 ENST00000382466.7 [Q5W0Z9-3] A0A0D9SEN4 L0R6T2 Q5W0Z9 ENST00000700725.1 ENST00000320220.13 [Q5W0Z9-4] ENST00000542645.5 |